Results 131 to 140 of about 2,994 (188)

MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. [PDF]

Clin Exp Immunol, 2021
Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J.   +5 more
europepmc   +1 more source

Thrombotic Microangiopathy [PDF]

American Journal of Kidney Diseases, 1999
openaire   +1 more source

The Interaction Between Coagulation and Complement Cascades in the Management of Thrombotic Microangiopathies Related to Postpartum Hemorrhage. [PDF]

Kidney Int Rep
Orsi M, Ossola MW, Cetin I, Ardissino G.
europepmc   +1 more source

Monitoring Complement Activation: The New Conundrum in Thrombotic Microangiopathies. [PDF]

Clin J Am Soc Nephrol, 2019
Fakhouri F, Frémeaux-Bacchi V.
europepmc   +1 more source

Complement Activation and Thrombotic Microangiopathies. [PDF]

Clin J Am Soc Nephrol, 2019
Palomo M, Blasco M, Molina P, Lozano M, Praga M, Torramade-Moix S, Martinez-Sanchez J, Cid J, Escolar G, Carreras E, Paules C, Crispi F, Quintana LF, Poch E, Rodas L, Goma E, Morelle J, Espinosa M, Morales E, Avila A, Cabello V, Ariceta G, Chocron S, Manrique J, Barros X, Martin N, Huerta A, Fraga-Rodriguez GM, Cao M, Martin M, Romera AM, Moreso F, Manonelles A, Gratacos E, Pereira A, Campistol JM, Diaz-Ricart M.   +36 more
europepmc   +1 more source

Etiology and Outcomes of Thrombotic Microangiopathies. [PDF]

Clin J Am Soc Nephrol, 2019
Bayer G, von Tokarski F, Thoreau B, Bauvois A, Barbet C, Cloarec S, Mérieau E, Lachot S, Garot D, Bernard L, Gyan E, Perrotin F, Pouplard C, Maillot F, Gatault P, Sautenet B, Rusch E, Buchler M, Vigneau C, Fakhouri F, Halimi JM.   +20 more
europepmc   +1 more source

HLA-DR-DQ associations, combined with PLASMIC score, are reliable predictors of acquired thrombotic thrombocytopenic purpura (aTTP) and aid in differentiating aTTP from other thrombotic microangiopathies. [PDF]

Hematol Transfus Cell Ther
Pandey S, Shrivastava A, Harville YI, Cottler-Fox M, Harville TO.   +4 more
europepmc   +1 more source

When to consider targeted therapies in thrombotic microangiopathies in the modern era: walking the tightrope between cost, safety, and efficacy. [PDF]

J Thromb Thrombolysis, 2020
Murphree CR, Olson SR, DeLoughery TG, Shatzel JJ.   +3 more
europepmc   +1 more source